Novo Nordisk extended its share repurchase, reaching a treasury shareholding of 1.2%
Novo Nordisk repurchased 23.09 million of its own B shares for DKK 6,758,876,433, bringing its treasury holdings to 51,889,876 B shares (1.2% of capital). The buyback continues under a programme launched on 6 May 2026 that allows purchases up to DKK 11,200,000,010.45 through 1 February 2027.
Key points
- Novo Nordisk continued its B‑share repurchase programme, launched on 6 May 2026, and by 13 October 2026 had bought back 23.09 million shares for DKK 6,758,876,433.
- The programme is part of an overall share repurchase of up to DKK 15 billion covering a 12‑month period starting 4 February 2026.
What happened
Novo Nordisk continued its B‑share repurchase programme, launched on 6 May 2026, and by 13 October 2026 had bought back 23.09 million shares for DKK 6,758,876,433. After these transactions the company's treasury position stands at 51,889,876 B shares, equal to 1.2% of authorized capital.
Terms
The programme is part of an overall share repurchase of up to DKK 15 billion covering a 12‑month period starting 4 February 2026. Under a sub‑programme launched on 6 May 2026, the company may repurchase B shares for up to DKK 11,200,000,010.45 through 1 February 2027.
What to watch
Investors should watch upcoming repurchase announcements to gauge how much of the allowed DKK 11,200,000,010.45 remains and how it will affect the company's cash reserves.
How the story developed
- ResultNovo Nordisk repurchased 18,325,000 B shares for DKK 5,526,186,488
- Result · this articleNovo Nordisk extended its share repurchase, reaching a treasury shareholding of 1.2%
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Novo Nordisk A S
A notification in your browser or on your phone when we publish about Novo Nordisk A S. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
